Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Belzutifan by Merck for Pancreatic Tumor: Likelihood of Approval
Belzutifan is under clinical development by Merck and currently in Phase II for Pancreatic Tumor. According to GlobalData, Phase II...
Data Insights
Belzutifan by Merck for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Belzutifan is under clinical development by Merck and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...